# **Complete Summary**

### **GUIDELINE TITLE**

Low back - lumbar & thoracic (acute & chronic).

# **BIBLIOGRAPHIC SOURCE(S)**

Work Loss Data Institute. Low back - lumbar & thoracic (acute & chronic). Corpus Christi (TX): Work Loss Data Institute; 2007 Jul 5. 393 p. [543 references]

### **GUIDELINE STATUS**

**Note**: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

### \*\* REGULATORY ALERT \*\*

### FDA WARNING/REGULATORY ALERT

**Note from the National Guideline Clearinghouse**: This guideline references a drug(s) for which important revised regulatory information has been released.

- May 2, 2007, Antidepressant drugs: Update to the existing black box warning
  on the prescribing information on all antidepressant medications to include
  warnings about the increased risks of suicidal thinking and behavior in young
  adults ages 18 to 24 years old during the first one to two months of
  treatment.
- May 2, 2007, Colchicine: Immediate drug recall for all strengths, sizes and lots of ApothéCure compounded injectable Colchicine sold within the last year due to recent deaths associated with the use of the product.
- <u>June 15, 2005, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</u>: U.S. Food and Drug Administration (FDA) recommended proposed labeling for both the prescription and over the counter (OTC) NSAIDs and a medication guide for the entire class of prescription products.
- April 7, 2005, Non-steroidal anti-inflammatory drugs (NSAIDS) (prescription and OTC, including ibuprofen and naproxen): FDA asked manufacturers of prescription and non-prescription (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) to revise their labeling to include more specific information about potential gastrointestinal (GI) and cardiovascular (CV) risks.

### **COMPLETE SUMMARY CONTENT**

\*\* REGULATORY ALERT \*\*
SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

### **SCOPE**

# **DISEASE/CONDITION(S)**

Work-related low back pain

### **GUIDELINE CATEGORY**

Diagnosis Evaluation Management Treatment

### **CLINICAL SPECIALTY**

Chiropractic
Family Practice
Internal Medicine
Orthopedic Surgery
Physical Medicine and Rehabilitation
Surgery

### **INTENDED USERS**

Advanced Practice Nurses Health Care Providers Health Plans Nurses Physician Assistants Physicians

# **GUIDELINE OBJECTIVE(S)**

To offer evidence-based step-by-step decision protocols for the assessment and treatment of workers' compensation conditions

### **TARGET POPULATION**

Workers with low back pain

### INTERVENTIONS AND PRACTICES CONSIDERED

The following interventions/procedures were considered and recommended as indicated in the original guideline document:

- 1. Activity restrictions/work modifications
- 2. Aerobic exercise
- 3. Age adjustment
- 4. Antidepressants in chronic cases
- 5. Anti-inflammatory medications (e.g., ibuprofen)
- 6. Aquatic therapy (as an optional form of exercise therapy)
- 7. Back schools
- 8. Behavioral treatment
- 9. Chiropractic/manipulation
- 10. Cold/heat packs for acute pain
- 11. Conservative care (first six months)
- 12. Differential diagnosis
- 13. Discectomy/laminectomy
- 14. Electromyography (needle, not surface)
- 15. Epidural steroid injections (ESIs) (treatment and diagnostic)
- 16. Evoked potential studies
- 17. Exercise
- 18. Facet joint diagnostic blocks (injections) prior to facet neurotomy
- 19. Facet joint pain, signs and symptoms
- 20. Fear-avoidance beliefs questionnaire (FABQ)
- 21. Fluoroscopy (for ESIs)
- 22. Hardware injection block for diagnostic evaluation of failed back surgery syndrome
- 23. Heat therapy
- 24. Herbal medicines
- 25. Home health services
- 26. H-reflex tests
- 27. Implantable drug-delivery systems (IDDSs) (as an end-stage treatment alternative)
- 28. Kyphoplasty
- 29. Lumbar extension exercise equipment
- 30. Magnetic resonance imaging (MRI)
- 31. Massage
- 32. McKenzie method
- 33. Microdiscectomy
- 34. Muscle relaxants for acute cases
- 35. Myelography
- 36. Nonprescription medications (e.g., acetaminophen, aspirin, ibuprofen) for early use only
- 37. Occupational/physical therapy
- 38. Patient education for treatment
- 39. Percutaneous vertebroplasty
- 40. Psychological screening prior to surgery
- 41. Return to work and regular activities
- 42. Segmental rigidity (diagnosis)
- 43. Shoe insoles/shoe lifts
- 44. Spinal cord stimulation (SCS) for selected patients
- 45. Stretching (as part of an exercise program)
- 46. Work conditioning/work hardening
- 47. Yoga

The following interventions/procedures were considered optional:

Shoe insoles/shoe lifts

The following interventions/procedures are under study and are not specifically recommended:

- 1. Acupressure
- 2. Adhesiolysis, spinal endoscopic
- 3. Back brace/corsets/lumbar supports for treatment
- 4. Bone-growth stimulators
- 5. Colchicine
- 6. Electromagnetic pulsed therapy
- 7. Ergonomic interventions for primary prevention
- 8. Facet joint intra-articular injections (therapeutic blocks)
- 9. Facet rhizotomy/facet joint radiofrequency neurotomy
- 10. Feldenkrais
- 11. Gabapentin
- 12. Magnetic resonance (MR) neurography
- 13. Mattress firmness
- 14. Percutaneous adhesiolysis/epidural neuroplasty
- 15. Percutaneous electrical nerve stimulation (PENS)

The following interventions/procedures were considered, but are not recommended:

- 1. Acupuncture
- 2. Back brace/corsets/lumbar supports for prevention
- 3. Bed rest
- 4. Biofeedback
- 5. Bone scan
- 6. Botulinum toxin (Botox)
- 7. Bupropion for low back pain
- 8. Chemonucleolysis (chymopapain)
- 9. Computed tomography (CT) and CT myelography
- 10. Cutaneous laser treatment
- 11. Current perception threshold (CPT) testing
- 12. Delayed treatment
- 13. Device for intervertebral assisted motion (DIAM)
- 14. Diathermy
- 15. Disc prosthesis/replacement
- 16. Discography
- 17. Dynamic neutralization system (Dynesys)
- 18. Epidural steroid injections, "series of three"
- 19. Facet-joint injections, thoracic
- 20. Facet joint medial branch blocks for therapy
- 21. Flexibility evaluation
- 22. Functional anesthetic discography
- 23. F-wave tests
- 24. Fusion (spinal, endoscopic)
- 25. Hospitalization except for major trauma
- 26. H-wave stimulation (devices)

- 27. Interferential therapy
- 28. Intradiscal electrothermal annuloplasty (IDET)
- 29. Intradiscal steroid injection
- 30. Iontophoresis
- 31. Ligamentous injections
- 32. Low level laser therapy (LLLT)
- 33. Lumbar supports for prevention
- 34. Magnet therapy
- 35. Manipulation under anesthesia (MUA)
- 36. Microcurrent electrical stimulation (MENS devices)
- 37. NC-stat nerve conduction studies/nerve conduction studies (NCS)
- 38. Neuromuscular electrical stimulators (NMES) (except for patients with specific criteria)
- 39. Neuroreflexotherapy
- 40. Nucleoplasty
- 41. Opioids/narcotics (except for short use with severe cases)
- 42. Oral corticosteroids
- 43. Orthotrac vest
- 44. Percutaneous discectomy (PCD)
- 45. Percutaneous endoscopic laser discectomy (PELD)
- 46. Percutaneous intradiscal radiofrequency (thermocoagulation)
- 47. Percutaneous neuromodulation therapy (PNT)
- 48. Powered traction devices
- 49. Prolotherapy, also known as sclerotherapy
- 50. Radiography in the absence of red flags
- 51. Single photon emission computed tomography (SPECT)
- 52. Standing MRI
- 53. Surface electromyography (SEMG)
- 54. Sympathetic therapy
- 55. Thermography (infrared stress thermography)
- 56. Traction
- 57. Transcutaneous electrical neurostimulation (TENS)
- 58. Transplantation, intravertebral disc
- 59. Trigger point injections in the absence of myofascial pain syndrome
- 60. Tumor necrosis factor modifiers
- 61. Ultrasound (diagnostic and therapeutic)
- 62. Vertebral axial decompression (VAX-D)/powered traction devices
- 63. Videofluoroscopy

### **MAJOR OUTCOMES CONSIDERED**

- Reliability and value of diagnostic assessments
- Effectiveness of treatment in relieving pain and restoring normal function

### **METHODOLOGY**

### METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources) Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

Work Loss Data Institute (WLDI) conducted a comprehensive medical literature review (now ongoing) with preference given to high quality systematic reviews, meta-analyses, and clinical trials published since 1993, plus existing nationally recognized treatment guidelines from the leading specialty societies. WLDI primarily searched MEDLINE and the Cochrane Library. In addition, WLDI also reviewed other relevant treatment guidelines, including those in the National Guideline Clearinghouse, as well as state guidelines and proprietary guidelines maintained in the WLDI guideline library. These guidelines were also used to suggest references or search terms that may otherwise have been missed. In addition, WLDI also searched other databases, including MD Consult, eMedicine, CINAHL, and conference proceedings in occupational health (i.e. American College of Occupational and Environmental medicine [ACOEM]) and disability evaluation (i.e. American Academy of Disability Evaluating Physicians [AADEP], American Board of Independent Medical Examiners [ABIME]). Search terms and questions were diagnosis, treatment, symptom, sign, and/or body-part driven, generated based on new or previously indexed existing evidence, treatment parameters and experience.

In searching the medical literature, answers to the following questions were sought: (1) If the diagnostic criteria for a given condition have changed since 1993, what are the new diagnostic criteria? (2) What occupational exposures or activities are associated causally with the condition? (3) What are the most effective methods and approaches for the early identification and diagnosis of the condition? (4) What historical information, clinical examination findings or ancillary test results (such as laboratory or x-ray studies) are of value in determining whether a condition was caused by the patient's employment? (5) What are the most effective methods and approaches for treating the condition? (6) What are the specific indications, if any, for surgery as a means of treating the condition? (7) What are the relative benefits and harms of the various surgical and non-surgical interventions that may be used to treat the condition? (8) What is the relationship, if any, between a patient's age, gender, socioeconomic status and/or racial or ethnic grouping and specific treatment outcomes for the condition? (9) What instruments or techniques, if any, accurately assess functional limitations in an individual with the condition? (10) What is the natural history of the disorder? (11) Prior to treatment, what are the typical functional limitations for an individual with the condition? (12) Following treatment, what are the typical functional limitations for an individual with the condition? (13) Following treatment, what are the most cost-effective methods for preventing the recurrence of signs or symptoms of the condition, and how does this vary depending upon patient-specific matters such as underlying health problems?

### Criteria for Selecting the Evidence

Preference was given to evidence that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial – randomized or controlled, or (4) The article reports a cohort study, whether prospective or retrospective, or (5) The article reports a case control series involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from

the persons or institution that performed the intervention the outcome of which is being assessed.

More information about the selection of evidence is available in "Appendix. ODG Treatment in Workers' Comp. Methodology description using the AGREE instrument" (see "Availability of Companion Documents" field).

### NUMBER OF SOURCE DOCUMENTS

Not stated

# METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

# Ranking by Type of Evidence

- 1. Systematic Review/Meta-Analysis
- 2. Controlled Trial-Randomized (RCT) or Controlled
- 3. Cohort Study-Prospective or Retrospective
- 4. Case Control Series
- 5. Unstructured Review
- 6. Nationally Recognized Treatment Guideline (from www.guideline.gov)
- 7. State Treatment Guideline
- 8. Other Treatment Guideline
- 9. Textbook
- 10. Conference Proceedings/Presentation Slides

# Ranking by Quality within Type of Evidence

- a. High Quality
- b. Medium Quality
- c. Low Quality

### METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses Systematic Review

### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

The Work Loss Data Institute (WLDI) reviewed each article that was relevant to answering the question at issue, with priority given to those that met the following criteria: (1) The article was written in the English language, and the article had any of the following attributes: (2) It was a systematic review of the relevant medical literature, or (3) The article reported a controlled trial – randomized or controlled, or (4) The article reported a cohort study, whether prospective or retrospective, or (5) The article reported a case control series

involving at least 25 subjects, in which the assessment of outcome was determined by a person or entity independent from the persons or institution that performed the intervention the outcome of which is being assessed.

Especially when articles on a specific topic that met the above criteria were limited in number and quality, WLDI also reviewed other articles that did not meet the above criteria, but all evidence was ranked alphanumerically (see the Rating Scheme of the Strength of Evidence field) so that the quality of evidence could be clearly determined when making decisions about what to recommend in the Guidelines. Articles with a Ranking by Type of Evidence of Case Reports and Case Series were not used in the evidence base for the Guidelines. These articles were not included because of their low quality (i.e., they tend to be anecdotal descriptions of what happened with no attempt to control for variables that might effect outcome). Not all the evidence provided by WLDI was eventually listed in the bibliography of the published Guidelines. Only the higher quality references were listed. The criteria for inclusion was a final ranking of 1a to 4b (the original inclusion criteria suggested the methodology subgroup), or if the Ranking by Type of Evidence was 5 to 10, the quality ranking should be an "a."

### METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

### RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

### **COST ANALYSIS**

The guideline developers reviewed published cost analyses.

### **METHOD OF GUIDELINE VALIDATION**

External Peer Review

# **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Prior to publication, select organizations and individuals making up a cross-section of medical specialties and typical end-users externally reviewed the guideline.

### **RECOMMENDATIONS**

### **MAJOR RECOMMENDATIONS**

**Note**: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.

# **Identify Radicular Signs**

- First visit: may be with Primary Care Physician MD/DO (50%), Orthopedist (33%), or Chiropractor (17%)
- Determine presence or absence of radiculopathy:
  - Medical history
  - Sensation: Feeling pain radiating below the knee (calf or lower), not just referred pain (pain radiating to buttocks or thighs), and dermatological sensory loss
  - Straight leg raising test (sitting and supine), productive of leg pain
  - Motor strength and deep tendon reflexes
  - Document flexibility/range of motion (ROM) (fingertip test), muscle atrophy (calf measurement), local areas of tenderness, visual pain analog, sensation alternation
  - Note: Radiculopathy is often over-diagnosed. For unequivocal evidence of radiculopathy, refer to the American Medical Association (AMA) Guides to the Evaluation of Permanent Impairment, 5<sup>th</sup> Edition, page 382-383.
- Rule out "red flag" diagnoses, including diagnostic studies, for specialist referral:
  - Cauda Equina Syndrome (Schedule emergency procedure) (Refer to the original guideline document for International Classification of Diseases, Ninth Revision [ICD-9] codes for this and other diagnoses)
  - Fracture, Compression fracture, Dislocation, Wound
  - Cancer, Infection
  - Dissecting/Ruptured Aortic Aneurysm
  - Others (prostate problems, endometriosis/gynecological disorders, urinary tract infections, and renal pathology)
  - **Note**: This guideline should not be used to suggest appropriate procedures for other conditions or comorbidities. When the treating doctor suspects any other diagnosis, they may decide what necessary testing should be performed, which may include laboratory tests such as erythrocyte sedimentation rate (ESR), complete blood count (CBC), and urinalysis (UA) to screen for nonspecific medical diseases (especially infection and tumor) of the low back.

# Without Radiculopathy (90% of cases)

- Also first visit (day 1):
  - Prescribe decreased activity, if necessary, based on severity and difficulty of job, limited passive therapy with heat/ice (3 to 4 times/day), stretching/exercise (training by physical therapist OK), appropriate analgesia (i.e., acetaminophen) and/or anti-inflammatory (i.e., ibuprofen) [Benchmark cost: \$14], back to work except for severe cases in 72 hours, possibly modified duty. Avoid bed rest.
  - No x-rays unless significant trauma (e.g., a fall)
  - If muscle spasms, then consider muscle relaxant with limited sedative side effects [Benchmark cost: \$44]

(**Note**: The purpose of muscle relaxants is to facilitate return to activity, but muscle relaxants have not been shown to be more effective than non-steroidal anti-inflammatory drugs [NSAIDs].)

 REASSURE PATIENT: patient education - common problem (90% of patients recover spontaneously in 4 weeks) Official Disability Guidelines (ODG) Return-To-Work Pathways (lumbar sprain and lumbago)

Modified Duty --

Mild, (Grade I)<sup>1</sup>, clerical/modified work: 0 days

Severe, (Grade II-III)<sup>1</sup>, clerical/modified work: 3 days

(See *ODG Capabilities* & *Activity Modifications for Restricted Work* under "Work" in the Procedure Summary for Ergonomic accommodations of the original guideline document)

<sup>1</sup>**Definition of Sprain/Strain Severity Grade**: In general, a Grade I or mild sprain/strain is caused by overstretching or slight tearing of the ligament/muscle/tendon with no instability, and a person with a mild sprain usually experiences minimal pain, swelling, and little or no loss of functional ability. Although the injured muscle is tender and painful, it has normal strength. A Grade II sprain/strain is caused by incomplete tearing of the ligament/muscle/tendon and is characterized by bruising, moderate pain, and swelling, and a Grade III sprain/strain means complete tear or rupture of a ligament/muscle/tendon. A sprain is a stretch and/or tear of a ligament (a band of fibrous tissue that connects two or more bones at a joint). A strain is an injury to either a muscle or a tendon (fibrous cords of tissue that connect muscle to bone).

- Second visit (day 3 to 10 about 1 week after first visit or sooner because delayed treatment is not recommended)
  - Document progress (flexibility, areas of tenderness, motor strength, straight leg raise--sitting and supine).
  - If still 50% disabled then consider referral for exercise/instruction/manual therapy [Benchmark cost: \$250]: Options are physical therapist, chiropractor, massage therapist, or occupational therapist (3 visits in first week), or by treating DO/MD (Choose providers supporting active therapy and not just passive modalities. The focus of treatment should not be symptom reduction, but improving function with a goal to return to work.) Consider screening for psychosocial symptoms in cases with expectations of delayed recovery.
  - Discontinue muscle relaxant.

**ODG Return-To-Work Pathways** (lumbar sprain and lumbago)

Manual Work --

Mild, manual work: 7 to 10 days

Severe, manual work: 14 to 17 days

- Third visit (day 10 to 17 about 1 week after second visit)
  - Document progress.
  - Prescribe muscle-conditioning exercises.
  - At this point 66% to 75% should be back to regular work.
  - While not indicated in the absence of red flags, if still disabled, then consider imaging study (anterior-posterior [AP]/lateral 2-view x-ray of

lumbar) [Benchmark cost: \$150] to rule out tumor, fracture, osteoporosis, myelopathy

- Maintain therapy, continue focus on active therapy and not passive modalities, 2 visits in next week, teach home exercises
- End manual therapy at 4 weeks (1 visit in last week)

# **ODG Return-To-Work Pathways** (lumbar sprain and lumbago)

Manual & Heavy Manual Work --

Severe, manual work: 14 to 17 days

Severe, heavy manual work: 35 days

# With Radiculopathy (10% of cases)

- Also first visit (day 1)
  - Same as non-radicular

# **ODG Return-To-Work Pathways** (intervertebral disc disorders)

Disc bulge --

Mild cases with back pain, avoid strenuous activity: 0 days

Herniated disc --

Initial conservative medical treatment, clerical/modified work: 3 days

- Second visit (day 3-10 about 1 week after first visit)
  - Same as non-radicular, but
  - Reassure, but if increased numbness or weakness of either leg, get back to provider in one day
  - Consider referral to nonsurgical musculoskeletal physician (Orthopedist/Physical Medicine/Sports Medicine).
- Third visit (day 10 to 17 about 1 week after second visit)
  - Same as non-radicular, but
  - About 50% can be back at modified duty.
  - If improvement, then add strengthening exercises, increased activity
- Fourth visit (day 21 to 28 about 1 to 2 weeks after third visit)
  - Document, if no improvement then:
  - First magnetic resonance imaging (MRI) (about 3% of total cases, or 30% of radicular cases) to confirm extruded disk with nerve root displacement (≥1 month conservative therapy) [Benchmark cost: \$1.600]
  - MRI or computed tomography (CT) not indicated without obvious clinical level of nerve root dysfunction, clear radicular findings, or before 3 to 4 weeks

- EMGs (electromyography) may be useful to obtain unequivocal evidence of radiculopathy, after 1-month conservative therapy, but EMGs are not necessary if radiculopathy is already clinically obvious.
- Consider an epidural steroid injection (ESI) for severe cases hoping to avoid surgery [Benchmark cost: \$676] (Note: The purpose of ESI is to reduce pain and inflammation, restoring range of motion and thereby facilitating progress in more active treatment programs, but this treatment alone offers no significant long-term functional benefit.)
- If psychological factors retarding recovery are suspected, possibly refer to psychologist for testing. [Benchmark cost: \$540]
- Education: Consider back school as an option, if available
- If no improvement 7 to 14 days after the first ESI, consider prescribing 2nd ESI [Benchmark cost: \$615]; there should be a maximum of two ESIs, and the second ESI can be 7 to 14 days after the first, depending upon the patient's response and functional gain.

# **ODG Return-To-Work Pathways** (intervertebral disc disorders)

Initial conservative medical treatment, manual work: 28 days

Initial conservative medical treatment, regular work if cause of disability: 84 days

- Surgery (three months or more -- after appropriate work-up and consultation, concordance between radicular findings on radiologic evaluation and physical exam findings) (about 2% of total cases, or 20% of radicular cases) (See also ODG Indications for Surgery™ -- Discectomy in the Procedure Summary of the original guideline document). Unequivocal objective findings are required based on neurological examination and testing.
  - Refer to fellowship trained Spine Surgeon: Neurosurgeon (50%), Orthopedist (50%)
  - Before surgery, screen for psychological symptoms that could affect surgical outcome (e.g., substance abuse, child abuse, work conflicts, somatization, verbalizations, attorney involvement, smoking).
  - Review options/outcomes with patient, let patient be part of decision making.
  - Simple discectomy/laminectomy, minimally invasive [Benchmark cost: \$17,400]
  - Post-operative pain, walking exercises, physical therapy

# **ODG Return-To-Work Pathways** (intervertebral disc disorders)

Discectomy, clerical/modified work: 28 days

Discectomy, manual work: 56 days

Discectomy, heavy manual work: 126 days to indefinite

Laminectomy, clerical/modified work: 28 days

Laminectomy, manual work: 70 days

Laminectomy, heavy manual work: 105 days to indefinite

• Failure to recover: See the Procedure Summary (in the original guideline document) for options that may be available, along with links to the medical evidence. Also see the Chronic Pain Chapter.

# **CLINICAL ALGORITHM(S)**

None provided

# **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

During the comprehensive medical literature review, preference was given to high quality systematic reviews, meta-analyses, and clinical trials over the past ten years, plus existing nationally recognized treatment guidelines from the leading specialty societies.

The heart of each Work Loss Data Institute guideline is the Procedure Summary (see the original guideline document), which provides a concise synopsis of effectiveness, if any, of each treatment method based on existing medical evidence. Each summary and subsequent recommendation is hyper-linked into the studies on which they are based, in abstract form, which have been ranked, highlighted and indexed.

# BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

### **POTENTIAL BENEFITS**

These guidelines unite evidence-based protocols for medical treatment with normative expectations for disability duration. They also bridge the interests of the many professional groups involved in diagnosing and treating work-related low back pain.

### **POTENTIAL HARMS**

Muscle relaxants have potential side effects, including drowsiness in up to 30 percent of patients.

### **QUALIFYING STATEMENTS**

# **QUALIFYING STATEMENTS**

The Treatment Planning sections outline the most common pathways to recovery, but there is no single approach that is right for every patient and these protocols do not mention every treatment that may be recommended. See the Procedure Summaries (in the original guideline document) for complete lists of the various options that may be available, along with links to the medical evidence.

### **IMPLEMENTATION OF THE GUIDELINE**

### **DESCRIPTION OF IMPLEMENTATION STRATEGY**

An implementation strategy was not provided.

### **IMPLEMENTATION TOOLS**

Patient Resources

For information about <u>availability</u>, see the "Availability of Companion Documents" and "Patient Resources" fields below.

# INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### **IOM CARE NEED**

Getting Better Living with Illness

### **IOM DOMAIN**

Effectiveness Patient-centeredness

# **IDENTIFYING INFORMATION AND AVAILABILITY**

# **BIBLIOGRAPHIC SOURCE(S)**

Work Loss Data Institute. Low back - lumbar & thoracic (acute & chronic). Corpus Christi (TX): Work Loss Data Institute; 2007 Jul 5. 393 p. [543 references]

### **ADAPTATION**

Not applicable: The guideline was not adapted from another source.

### **DATE RELEASED**

2003 (revised 2007 Jun 12)

# **GUIDELINE DEVELOPER(S)**

Work Loss Data Institute - Public For Profit Organization

# **SOURCE(S) OF FUNDING**

Not stated

### **GUIDELINE COMMITTEE**

Not stated

### **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

Editor-in-Chief, Philip L. Denniston, Jr. and Senior Medical Editor, Charles W. Kennedy, MD, together pilot the group of approximately 80 members. See the ODG *Treatment in Workers Comp* Editorial Advisory Board.

# FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

There are no conflicts of interest among the guideline development members.

### **GUIDELINE STATUS**

**Note**: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

### **GUIDELINE AVAILABILITY**

Electronic copies of the updated guideline: Available to subscribers from the <u>Work</u> Loss Data Institute Web site.

Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9992, Fax: 760-753-9995; <a href="https://www.worklossdata.com">www.worklossdata.com</a>.

### **AVAILABILITY OF COMPANION DOCUMENTS**

The following are available:

- Background information on the development of the Official Disability
  Guidelines of the Work Loss Data Institute is available from the Work Loss
  Data Institute Web site.
- Appendix. ODG Treatment in Workers' Comp. Methodology description using the AGREE instrument. Available to subscribers from the <u>Work Loss Data</u> Institute Web site.

### **PATIENT RESOURCES**

The following is available:

Appendix B. ODG Treatment in Workers' Comp. Patient information resources.
 2006.

Electronic copies: Available to subscribers from the <u>Work Loss Data Institute Web</u> site.

Print copies: Available from the Work Loss Data Institute, 169 Saxony Road, Suite 210, Encinitas, CA 92024; Phone: 800-488-5548, 760-753-9995; www.worklossdata.com.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

# **NGC STATUS**

This summary was completed by ECRI on February 2, 2004. The information was verified by the guideline developer on February 13, 2004. This NGC summary was updated by ECRI on March 28, 2005, January 3, 2006, April 11, 2006, November 10, 2006, and March 30, 2007. This summary was updated by ECRI Institute on May 17, 2007 following the U.S. Food and Drug advisory on Colchicine. This NGC summary was updated by ECRI Institute on August 28, 2007. This summary was updated by ECRI Institute on October 31, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs.

### **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

### **DISCLAIMER**

# **NGC DISCLAIMER**

The National Guideline Clearinghouse<sup>™</sup> (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href="http://www.guideline.gov/about/inclusion.aspx">http://www.guideline.gov/about/inclusion.aspx</a>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion

or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/15/2008

